Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2012 - 2026)

Enanta Pharmaceuticals' Cash & Current Investments history runs 15 years deep, the most recent figure standing at $163.8 million for Q1 2026.

• Quarterly Cash & Current Investments fell 15.31% year-over-year to $163.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.8 million (down 15.31% YoY) and the FY2025 annual result came in at $188.9 million, up 399.1% from the prior year.
• Cash & Current Investments was $163.8 million for Q1 2026 at Enanta Pharmaceuticals, down from $185.8 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $386.6 million in Q2 2023 and bottomed at $37.8 million in Q3 2024.
• A 5-year average of $210.5 million and a median of $214.5 million in 2022 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 399.1% in 2025, while the deepest fall reached 80.52% in 2025.
• Enanta Pharmaceuticals' Cash & Current Investments stood at $214.5 million in 2022, then surged by 57.2% to $337.2 million in 2023, then tumbled by 35.73% to $216.7 million in 2024, then declined by 14.23% to $185.8 million in 2025, then decreased by 11.88% to $163.8 million in 2026.
• Business Quant data shows ENTA's Cash & Current Investments at $163.8 million in Q1 2026, $185.8 million in Q4 2025, and $188.9 million in Q3 2025.